- Home
- FOSL vs ATOS Comparison
FOSL vs ATOS Comparison
Compare FOSL & ATOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FOSL
- ATOS
- Stock Information
- Founded
- FOSL 1984
- ATOS 2009
- Country
- FOSL United States
- ATOS United States
- Employees
- FOSL N/A
- ATOS N/A
- Industry
- FOSL Consumer Specialties
- ATOS Biotechnology: Pharmaceutical Preparations
- Sector
- FOSL Consumer Discretionary
- ATOS Health Care
- Exchange
- FOSL Nasdaq
- ATOS Nasdaq
- Market Cap
- FOSL 100.0M
- ATOS 107.2M
- IPO Year
- FOSL 1993
- ATOS 2012
- Fundamental
- Price
- FOSL $3.07
- ATOS $0.79
- Analyst Decision
- FOSL Strong Buy
- ATOS Strong Buy
- Analyst Count
- FOSL 1
- ATOS 3
- Target Price
- FOSL $5.00
- ATOS $6.17
- AVG Volume (30 Days)
- FOSL 1.3M
- ATOS 502.4K
- Earning Date
- FOSL 11-06-2025
- ATOS 08-12-2025
- Dividend Yield
- FOSL N/A
- ATOS N/A
- EPS Growth
- FOSL N/A
- ATOS N/A
- EPS
- FOSL N/A
- ATOS N/A
- Revenue
- FOSL $1,083,797,000.00
- ATOS N/A
- Revenue This Year
- FOSL N/A
- ATOS N/A
- Revenue Next Year
- FOSL N/A
- ATOS N/A
- P/E Ratio
- FOSL N/A
- ATOS N/A
- Revenue Growth
- FOSL N/A
- ATOS N/A
- 52 Week Low
- FOSL $0.86
- ATOS $0.55
- 52 Week High
- FOSL $3.58
- ATOS $1.66
- Technical
- Relative Strength Index (RSI)
- FOSL 63.06
- ATOS 50.57
- Support Level
- FOSL $2.91
- ATOS $0.81
- Resistance Level
- FOSL $3.20
- ATOS $0.80
- Average True Range (ATR)
- FOSL 0.28
- ATOS 0.03
- MACD
- FOSL 0.01
- ATOS 0.01
- Stochastic Oscillator
- FOSL 34.62
- ATOS 82.86
About FOSL Fossil Group Inc.
Fossil Group Inc is a design, innovation and distribution company in consumer fashion accessories. The products include traditional watches, smartwatches, jewelry, handbags, small leather goods, belts and sunglasses. The reportable segments are comprised of 1) Americas segment includes sales in Canada, Latin America and the United States. 2) Europe segment includes sales in European countries, the Middle East and Africa. 3) Asia segment includes sales in Australia, China, India, Indonesia, Japan, Malaysia, New Zealand, Singapore, South Korea and Thailand. Each reportable operating segment includes sales to wholesale and distributor customers, and sales through Company-owned retail stores and e-commerce activities based on the location of the selling entity.
About ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.